Literature DB >> 9706047

Transbuccal delivery of acyclovir: I. In vitro determination of routes of buccal transport.

A H Shojaei1, B Berner, L Xiaoling.   

Abstract

PURPOSE: To determine the major routes of buccal transport of acyclovir and to examine the effects of pH and permeation enhancer on drug permeation.
METHODS: Permeation of acyclovir across porcine buccal mucosa was studied by using side-by-side through diffusion cells at 37 degrees C. The permeability of acyclovir was determined at pH range of 3.3 to 8.8. Permeability of different ionic species was calculated by fitting the permeation of data to a mathematical model. Acyclovir was quantified using HPLC.
RESULTS: Higher steady state fluxes were observed at pH 3.3 and 8.8. The partition coefficient (1-octanol/buffer) and the solubility of acyclovir showed the same pH dependent profile as that of drug permeation. In the presence of sodium glycocholate (NaGC) (2-100 mM), the permeability of acyclovir across buccal mucosa was increased 2 to 9 times. This enhancement was independent of pH and reached a plateau above the critical micelle concentration of NaGC. The permeabilities of anionic, cationic, and zwitterionic species were 3.83 X 10-5, 4.33 X 10-5, and 6.24 x 10-6 cm/sec, respectively.
CONCLUSIONS: The in vitro permeability of acyclovir across porcine buccal mucosa and the octanol-water partitioning of the drug were pH dependent. A model of the paracellular permeation of the anionic, cationic, and zwitterionic forms of acyclovir is consistent with these data. The paracellular route was the primary route of buccal transport of acyclovir, and the enhancement of transbuccal transport of acyclovir by sodium glycocholate (NaGC) appeared to operate via this paracellular route.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9706047     DOI: 10.1023/a:1011927521627

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  Autoradiographic study of the penetration of radiolabelled dextrans and inulin through non-keratinized oral mucosa in vitro.

Authors:  M C Alfano; A I Chasens; C W Masi
Journal:  J Periodontal Res       Date:  1977-09       Impact factor: 4.419

2.  The permeability of skin and oral mucosa to water and horseradish peroxidase as related to the thickness of the permeability barrier.

Authors:  C A Squier; B K Hall
Journal:  J Invest Dermatol       Date:  1985-03       Impact factor: 8.551

3.  The influence of substitution in phenylacetic acids on their performance in the buccal absorption test.

Authors:  A H Beckett; A C Moffat
Journal:  J Pharm Pharmacol       Date:  1969-12       Impact factor: 3.765

4.  Correlation of partition coefficients in n-heptane-aqueous systems with buccal absorption data for a series of amines and acids.

Authors:  A H Beckett; A C Moffat
Journal:  J Pharm Pharmacol       Date:  1969-12       Impact factor: 3.765

5.  Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes.

Authors:  A H Beckett; E J Triggs
Journal:  J Pharm Pharmacol       Date:  1967-12       Impact factor: 3.765

6.  Mechanisms of non-electrolyte penetration across dog and rabbit oral mucosa in vitro.

Authors:  I A Siegel; K T Izutsu; E Watson
Journal:  Arch Oral Biol       Date:  1981       Impact factor: 2.633

7.  GI absorption of beta-lactam antibiotics II: deviation from pH--partition hypothesis in penicillin absorption through in situ and in vitro lipoidal barriers.

Authors:  A Tsuji; E Miyamoto; N Hashimoto; T Yamana
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

8.  Lipid content and water permeability of skin and oral mucosa.

Authors:  C A Squier; P Cox; P W Wertz
Journal:  J Invest Dermatol       Date:  1991-01       Impact factor: 8.551

9.  Influence of pH on the buccal absorption of morphine sulphate and its major metabolite, morphine-3-glucuronide.

Authors:  O Al-Sayed-Omar; A Johnston; P Turner
Journal:  J Pharm Pharmacol       Date:  1987-11       Impact factor: 3.765

10.  Diffusion rates and transport pathways of fluorescein isothiocyanate (FITC)-labeled model compounds through buccal epithelium.

Authors:  A J Hoogstraate; C Cullander; J F Nagelkerke; S Senel; J C Verhoef; H E Junginger; H E Boddé
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

View more
  7 in total

1.  Mucoadhesive fenretinide patches for site-specific chemoprevention of oral cancer: enhancement of oral mucosal permeation of fenretinide by coincorporation of propylene glycol and menthol.

Authors:  Xiao Wu; Kashappa-Goud H Desai; Susan R Mallery; Andrew S Holpuch; Maynard P Phelps; Steven P Schwendeman
Journal:  Mol Pharm       Date:  2012-03-06       Impact factor: 4.939

2.  Effect of drug lipophilicity and ionization on permeability across the buccal mucosa: a technical note.

Authors:  Amit Kokate; Xiaoling Li; Bhaskara Jasti
Journal:  AAPS PharmSciTech       Date:  2008-03-20       Impact factor: 3.246

3.  Mucoadhesive drug delivery systems.

Authors:  Rahamatullah Shaikh; Thakur Raghu Raj Singh; Martin James Garland; A David Woolfson; Ryan F Donnelly
Journal:  J Pharm Bioallied Sci       Date:  2011-01

4.  Layered nanoemulsions as mucoadhesive buccal systems for controlled delivery of oral cancer therapeutics.

Authors:  Amy Gavin; Jimmy Th Pham; Dawei Wang; Bill Brownlow; Tamer A Elbayoumi
Journal:  Int J Nanomedicine       Date:  2015-02-23

5.  Preparation and evaluation of novel in situ gels containing acyclovir for the treatment of oral herpes simplex virus infections.

Authors:  Binu Chaudhary; Surajpal Verma
Journal:  ScientificWorldJournal       Date:  2014-03-24

6.  Formulation and evaluation of bucco-adhesive tablets of sumatriptan succinate.

Authors:  R Indira Prasanna; P Anitha; C Madhusudhana Chetty
Journal:  Int J Pharm Investig       Date:  2011-07

7.  Design, evaluation and in vitro - in vivo correlation of glibenclamide buccoadhesive films.

Authors:  R Indira Prasanna; K Uma Sankari
Journal:  Int J Pharm Investig       Date:  2012-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.